Articles from Ashvattha Therapeutics

Ashvattha will present Phase 2 data on migaldendranib, a subcutaneous therapy for DME and wet AMD, which could offer a more patient-friendly alternative to current injection-based treatments

REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics ("Ashvattha"), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target and reprogram activated cells in regions of inflammation, today announced positive interim Phase 2 results for migaldendranib (MGB), a novel subcutaneously administered nanomedicine treatment for retinal vascular diseases. Updated results were presented in a poster session at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting taking place May 4 – May 8, 2025, in Salt Lake City, UT.

Presentations to highlight updated Phase 2 subcutaneous migaldendranib (MGB) data for wet AMD and DME

New Clinical Advisory Board brings together distinguished retinal specialists to provide strategic guidance on development of Ashvattha's innovative nanomedicine programs

REDWOOD CITY, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target and reprogram activated cells in regions of inflammation, today announced positive Phase 2 data for Migaldendranib (MGB; D-4517.2), a novel subcutaneously (subQ) administered nanomedicine treatment for retinal diseases. SubQ administered MGB selectively targets and reduces fluid production in the retina of both eyes to reduce the need for therapies that remove the fluid after an injection in the eye.  Over 50 subjects have been treated to date across three clinical trials. The interim results of the chronic subQ MGB dosing Phase 2 study for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) were presented at the Angiogenesis, Exudation, and Degeneration 2025 virtual meeting on February 8, 2025.

REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target and reprogram activated cells in regions of inflammation, today announced upcoming presentations at Angiogenesis, Exudation, and Degeneration 2025 virtual meeting on February 8, 2025 and the BIO CEO & Investor Conference being held on February 10-11, 2025 at the New York Marriott Marquis in New York City.

REDWOOD CITY, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target and reprogram activated cells in regions of inflammation, today announced additional financing as an extension of its Series B of up to $50 million led by Tribe Capital with existing investors led by Natural Capital. The funding will enable Ashvattha to complete the ongoing Phase 2 ophthalmology trial and Phase 1/2 neuroinflammation trial.

Ashvattha Therapeutics, a clinical stage biotech company focused on novel hydroxyl dendrimer therapeutics (HDTs) targeting unmet medical needs in neurology, neuro-oncology, and ophthalmology, today announced it will present two oral presentations at the virtual World Molecular Imaging Congress (WMIC), on October 5-8, 2021.

Ashvattha Therapeutics, a clinical stage biotech company focused on novel hydroxyl dendrimer therapeutics (HDTs) targeting unmet medical needs in neurology, neuro-oncology, and ophthalmology, today announced that Jeffrey Cleland, Ph.D., Chairman, CEO and President will be presenting at the following upcoming virtual and in-person investor conferences:

Ashvattha Therapeutics, a clinical stage biotech company focused on novel hydroxyl dendrimer therapeutics (HDTs) targeting unmet medical needs in neurology, neuro-oncology, and ophthalmology, today announced positive interim results from its ongoing multicenter Phase 2 PRANA clinical study of the HDT, OP-101, to treat hyperinflammation in hospitalized adults with severe COVID-19.

Ashvattha Therapeutics, a clinical stage biotech company focused on novel hydroxyl dendrimer therapeutics (HDTs) targeting unmet medical needs in neuro-oncology, neurology and ophthalmology, today announced that it will present at the Sachs 7th Annual Immuno-Oncology Innovation Forum, held virtually, May 18-20, 2021.

Ashvattha Therapeutics, a biotech company focused on novel hydroxyl dendrimer therapeutics (HDTs) targeting unmet medical needs in neuro-oncology, neurology and ophthalmology, today announced the presentation of a virtual poster supporting the development of its proprietary HDT, D-4517, for treatment of wet age-related macular disease (AMD) at the 2021 Association for Vision and Ophthalmology (ARVO) Annual Meeting, held virtually, May 1-7.